EUVIMEDEUVIMED entdecken
Crossref

Microbiota transplant therapy improves ulcerative colitis symptoms independent of donor engraftment in a pilot randomized placebo-controlled trial

Daphne Moutsoglou iD, William A Nickols, Dina C Belhasan, Levi Teigen, Sharon Lopez, Lulu Chen, Amanda J Kabage, Monika Fischer, Christopher Staley iD, Alexander Khoruts iD, Byron P Vaughn iD

Inflammatory Bowel Diseases · 14.11.2026

DOI: 10.1093/ibd/izag236 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 14.11.2026. Verfasst von Daphne Moutsoglou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Section, Minneapolis VA Health Care System, Minneapolis, MN 55417, United States. Die Arbeit nennt 30 Literaturangaben. Gefördert von: NIH HHS, the University of Minnesota Physician Scientist Training Program, Pfizer Aspire.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Several clinical trials have assessed microbiota transplant therapy (MTT) in ulcerative colitis (UC); however, none have assessed a standardized MTT product. We developed a standardized, oral, lyophilized MTT product and previously reported the primary endpoint of engraftment at week 12. Here, we assessed clinical outcomes and the association with donor engraftment.

Methods

A single-center, randomized, double-blind, placebo-controlled pilot trial of patients with UC with an endoscopic Mayo score ≥1, who received MTT or placebo for 8 weeks. Symptom and fecal assessments occurred at baseline and weeks 4, 8, and 12. Secondary outcomes included the partial Mayo score (pMS) and correlation to donor engraftment. Stool microbiota were assessed via 16S rRNA sequencing and donor engraftment measured using SourceTracker.

Results

Participants receiving MTT (n = 13) had significantly higher donor engraftment at all measured time points compared with placebo (n = 14). Compared with baseline symptoms, participants who received MTT had significantly lower pMS at weeks 4 and 8, while no significant changes in pMS were noted in those randomized to placebo. There was no correlation between donor engraftment and pMS or clinical response. There was no significant pattern in engrafting donor taxa in those that met the threshold of clinical response at week 4 vs participants that did not meet clinical response.

Conclusions

Daily dosing of encapsulated MTT for 8 weeks reduces symptoms of UC as measured by the pMS. However, donor engraftment did not correlate to pMS or clinical responses. NCT03948919, Fecal Transplant for Ulcerative Colitis, https://clinicaltrials.gov/study/NCT03948919

Schlagwörter

Stichwörter der Autor:innen

fecal microbiota transplantinflammatory bowel diseasemicrobiota based therapeutics

Autor:innen und Institutionen

  • Gastroenterology Section, Minneapolis VA Health Care System, Minneapolis, MN 55417, United States.
  • Department of Medicine, University of Minnesota, Minneapolis, MN 55455, United States.
  • Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02115, United States.
  • Harvard Chan Microbiome in Public Health Center, Harvard T.H. Chan School of Public Health, Boston, MA 02115, United States.
  • Department of Food Science and Nutrition, University of Minnesota, St. Paul, MN 55108, United States.
  • Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, MN 55455, United States.

ORCID-Profile: Daphne Moutsoglou, Christopher Staley, Alexander Khoruts, Byron P Vaughn

Förderung

  • NIH HHS
  • the University of Minnesota Physician Scientist Training Program
  • Pfizer Aspire
  • NIGMS NIH HHS
  • National Institutes of Health
  • National Institute of General Medical Sciences

Zitieren

APA

Moutsoglou, D., Nickols, W. A., Belhasan, D. C., Teigen, L., Lopez, S., Chen, L., Kabage, A. J., Fischer, M., Staley, C., Khoruts, A., & Vaughn, B. P. (2026). Microbiota transplant therapy improves ulcerative colitis symptoms independent of donor engraftment in a pilot randomized placebo-controlled trial. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izag236

Vancouver

Moutsoglou D, Nickols WA, Belhasan DC, Teigen L, Lopez S, Chen L, et al. Microbiota transplant therapy improves ulcerative colitis symptoms independent of donor engraftment in a pilot randomized placebo-controlled trial. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izag236

BibTeX
@article{Moutsoglou2026,
  author = {Moutsoglou, Daphne and Nickols, William A and Belhasan, Dina C and Teigen, Levi and Lopez, Sharon and Chen, Lulu and Kabage, Amanda J and Fischer, Monika and Staley, Christopher and Khoruts, Alexander and Vaughn, Byron P},
  title = {Microbiota transplant therapy improves ulcerative colitis symptoms independent of donor engraftment in a pilot randomized placebo-controlled trial},
  journal = {Inflammatory Bowel Diseases},
  year = {2026},
  doi = {10.1093/ibd/izag236}
}
Kostenlos starten →